Full Press Release Details
28.07.2026
2026 Announcements
Clinical
News
Update: SCENESSE® in vitiligo
SCENESSE® and adjuvant narrowband UVB to be evaluated
Melbourne, Australia, 28 July 2026
ASX:
CUV
Frankfurt Borse:
UR9
ADS:
CUVL
Download PDF
CUVL Positive Sentiment
Update: SCENESSE® in vitiligo
Key Takeaway: The article announces an evaluation of SCENESSE® in combination with adjuvant narrowband UVB for the treatment of vitiligo. This evaluation is part of ongoing clinical developments in Melbourne, Australia. The news highlights a positive step forward in exploring new treatment options for this condition.
Price reaction · baseline $7.01 (2026-07-27 close) · hit after-hours · 1 other CUVL headline(s) in the window, move may be shared
day 0 close · peak
-2.6%
Market Sentiment Analysis
POSITIVE FACTORS
- SCENESSE® is being evaluated for vitiligo treatment.
- The combination with narrowband UVB shows potential.
- Clinical evaluation indicates progress in treatment options.
Frequently Asked Questions
What is SCENESSE® being evaluated for?
SCENESSE® is being evaluated for the treatment of vitiligo.
What combination is being tested with SCENESSE®?
It is being tested in combination with adjuvant narrowband UVB.
Where is the evaluation taking place?
The evaluation is taking place in Melbourne, Australia.
What is the significance of this evaluation?
This evaluation represents progress in exploring new treatment options for vitiligo.